Home » UK Drug Discovery Company Oxagen Completes $59.8 Million Financing
UK Drug Discovery Company Oxagen Completes $59.8 Million Financing
Oxagen Ltd, a drug discovery and development company specializing in inflammation, announced Monday the successful completion of a $59.8 Million (GBP31.6 Million) Series B round led by MPM Capital. The proceeds of the funding will be used to advance Oxagen's lead programme, a novel small molecule anti-inflammatory for asthma to the clinic and to expand the company's clinical and preclinical stage portfolio.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May